The emerging role of CD44 in regulating skeletal micrometastasis

Cancer Letters

Volumn 237, Issue 1, 2006, Pages 1-9

  Hill, Ashleigh ^a   McFarlane, Suzanne ^a   Johnston, Patrick G ^a   Waugh, David J J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bone; Cancer; Cathepsin K; CD44; Hyaluronan; Metastasis; MMP 9

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID;

BONE MARROW; BONE MATRIX; BONE METASTASIS; CANCER CELL; ENDOTHELIUM CELL; HEMATOLOGIC MALIGNANCY; HUMAN; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SOLID TUMOR;

EID: 33646536589     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.006     Document Type: Review

References (70)

1. Wai P.Y., and Kuo P.C. The role of osteopontin in tumour metastasis. J. Surg. Res. 121 (2004) 228-241
2. Borland G., Ross J.A., and Guy K. Forms and functions of CD44. Immunology 93 (1998) 139-148
3. Ponta H., Wainwright D., and Herrlich P. The CD44 protein family. Int. J. Biochem. Cell Biol. 30 (1998) 299-305
4. Rudzki Z., and Jothy S. CD44 and the adhesion of neoplastic cells. J. Clin. Pathol. Mol. Pathol. 50 (1997) 57
5. Lesley J., and Hyman R. CD44 structure and function. Front. Biosci. 3 (1998) 616-630
6. Bajorath J. Molecular organisation, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 39 (2000) 103-111
7. Isacke C.M., and Yarwood H. The hyaluronan receptor CD44. Int. J. Biochem. Cell Biol. 34 (2002) 718-721
8. Auvinen P., Tammi R., Parkkinen J., Tammi M., Agren U., Johannson R., et al. Hyaluronan in peritumoural stroma and malignant cells associate with breast cancer spreading and predicts survival. Am. J. Pathol. 156 (2000) 529-536
9. Lipponen P., Aaltomaa S., Tammi R., Tammi T., Agren U., and Kosma V.M. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur. J. Cancer 37 (2001) 849-856
10. Toole B.P. Hyaluronan promotes the malignant phenotype. Glycobiology 12 (2002) 37-42
11. Berner H.S., and Nesland J.M. Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast. Breast Cancer Res. Treat. 65 (2001) 23-29
12. Kinoshita J., Haga S., Shimizu T., Imamura H., Watanabe O., and Kajiwara T. The expression of variant exon v7-v8 CD44 antigen in relation to lymphatic metastasis of human breast cancer. Breast Cancer Res. Treat. 53 (1999) 177-183
13. Weber G.F., Bronson R.T., Ilagan J., Cantor H., Scmits R., and Maks T.W. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 62 (2002) 2281-2286
14. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumourigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988
15. Mundy G.R. Mechanisms of bone metastasis. Cancer (Suppl.) 80 (1997) 1546-1556
16. Roodman G.D. Mechanisms of bone metastasis. N. Eng. J. Med. 350 (2004) 1655-1664
17. Troen B.R. Molecular mechanisms underlying osteoclast formation and activation. Exp. Gerontol. 38 (2003) 605-614
18. Yin J.J., Pollock C.B., and Kelly K. Mechanisms of metastasis to bone. Cell Res. 15 (2005) 57-62
19. Kakonen S.M., and Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (Suppl.) 97 (2003) 834-839
20. Orr F.W., Lee J., Duivenvoorden W.C.M., and Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer (Suppl.) 88 (2000) 2912-2918
21. Martin T.J. Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J. Clin. Invest. 110 (2002) 1399-1401
22. Martin T.J., and Moseley J.M. Mechanisms in the skeletal complications of breast cancer. Endocr. Relat. Cancer 7 (2000) 271-284
23. Guise T.A., Yin J.J., and Mohammad K.S. Role of endothelin-1 in osteoblastic bone metastases. Cancer (Suppl.) 97 (2003) 779-784
24. Chiao J.W., Moonga B.S., Yang Y.M., Kancherla R., Mittelman A., Wu-Wong J.R., et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer 83 (2000) 360-365
25. Mohammad K.S., and Guise T.A. Endothelins in bone cancer metastasis. Cancer Treat. Res. 118 (2004) 197-212
26. McCarthy T.L., Ji C., Chen Y., Kim K.K., Imagawa M., Ito Y., et al. Runt domain factor (Runx)-dependent effects on CCAAT/enhancer-binding protein delta expression and activity in osteoblasts. J. Biol. Chem. 275 (2000) 21746-21753
27. Lehr J.E., and Pienta K.J. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J. Natl. Cancer Inst. 90 (1998) 118-123
28. Worthylake R.A., and Burridge R. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr. Opin. Cell Biol. 13 (2001) 569-577
29. DeGrendele H.C., Estess P., Picker L.J., and Siegelman M.H. CD44 and its ligand hyaluronate mediat e rolling under physiologic flow: a novel lymphocyte/endothelial cell primary adhesion pathway. J. Exp. Med. 183 (1996) 1119-11130
30. Nandi A., Estess P., and Siegelman M.H. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J. Biol. Chem. 275 (2000) 14939-14948
31. DeGrendele H.C., Estess P., and Siegelman M.H. Requirement for CD44 in activated T Cell extravasation into an inflammatory site. Science 278 (1997) 672-675
32. Okada T., and Hawley R.G. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int. J. Cancer 63 (1995) 823-830
33. Draffin J.E., McFarlane S., Hill A., Johnston P.G., and Waugh D.J.J. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res. 64 (2004) 5702-5711
34. Simpson M.A., Reiland J., Burger S.R., Furcht L.T., Spicer A.P., Oegema Jr. T.R., and McCarthy J.B. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J. Biol. Chem. 276 (2001) 17949-17957
35. Simpson M.A., Wilson C.M., Furcht L.T., Spicer A.P., Oegema Jr. T.R., and McCarthy J.B. Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J. Biol. Chem. 277 (2002) 10050-10057
36. Simpson M.A., Wilson C.M., and McCarthy J.B. Inhibition of prostate tumour cell hyaluronan synthesis impairs subcutaneous growth and vascularisation in immunocompromised mice. Am. J. Pathol. 161 (2002) 849-857
37. Avigdor A., Goichberg P., Shivtiel S., Dar A., Peled A., Samira S., et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103 (2004) 2981-2989
38. Eilon G., and Mundy G.R. Direct resorption of bone by human breast cancer cells in vitro. Nature 276 (1978) 726-728
39. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89 (1997) 1260-1270
40. Curran S., and Murray G.I. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer 36 (2000) 1621-1630
41. Chang C., and Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11 (2001) 37-43
42. Stamenkovic I. Matrix metalloproteinases in tumour invasion and metastasis. Semin. Cancer Biol. 10 (2000) 415-433
43. Stetler-Stevenson W.G., and Yu A.E. Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11 (2001) 143-152
44. Bourguignon L.Y., Gunja-Smith Z., Iida N., Zhu H.B., Young L.J., Muller W.J., et al. CD44v(3,8,10) is involved in cytoskeleton-mediated tumour cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176 (1998) 206-215
45. Yu Q., and Stamenkovic I. Localisation of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44 mediated tumour invasion. Genes Dev. 13 (1999) 35-48
46. Yu Q., and Stamenkovic I. Cell surface-localised matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumour invasion and angiogenesis. Genes Dev. 14 (2000) 163-176
47. Pfeilschifter J., and Mundy G.R. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA 84 (1987) 2024-2028
48. Cramer S.D., Chen Z., and Peehl D.M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156 (1996) 526-531
49. Killian C.S., Corral D.A., Kawinski E., and Constantine R.I. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 192 (1993) 940-947
50. Lindeman J.H.N., Hanemaaijer R., Mulder A., Sander Dijkstra P.D., Szuhai K., Bromme D., et al. Cathepsin K is the principal protease in giant cell tumour of the bone. Am. J. Pathol. 165 (2004) 593-600
51. Lark M.W., Stroup G.B., James I.E., Dodds R.A., Hwang S.M., Blake S.M., et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB331750) prevents bone matrix resorption in the ovariectomised rat. Bone 30 (2002) 746-753
52. Corey E., Brown L.G., Quinn J.E., Poot M., Roudier M.P., Higano C.S., et al. Zoledronic acid exhibits inhibitory effects o osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. 9 (2003) 295-306
53. Littlewood-Evans A.J., Bilbe G., Bowler W.B., Farley D., Wlodarski B., Kokubo T., et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57 (1997) 5386-5390
54. Ishibashi, Mori Y., Kurokawa T., and Kumegawa M. Breast cancer cells express cathepsins B and L but not cathepsin K or H. Cancer Biochem. Biophys. 17 (1999) 69-78
55. Bourguignon L.Y., Singleton P.A., Zhu H., and Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signalling leading to cytokine (macrophage-colony stimulating factor) production and breast tumour progression. J. Biol. Chem. 278 (2003) 29420-29434
56. McKee C.M., Penno M.B., Cowman M., Burdick M.D., Strieter R.M., Bao C., et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J. Clin. Invest. 98 (1996) 2403-2413
57. Hodge-Dufour J., Noble P.W., Horton M.R., Bao C., Wysoka M., Burdick M.D., et al. E Pure, Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J. Immunol. 159 (1997) 2492-2500
58. Lin Y.H., Huang C.J., Chao J.R., Chen S.T., Lee S.F., Yen J.J., et al. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol. Cell Biol. 20 (2000) 2734-2742
59. Sundstrom G., Dahl I.M., Hultdin M., Lundstrom B., Wahlin A., and Engstrom-Laurent A. Bone marrow hyaluronan distribution in patients with acute myeloid leukaemia. Med. Oncol. 22 (2005) 71-78
60. Calabro A., Oken M.M., Hascall V.C., and Masellis A.M. Characterisation of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. Blood 100 (2002) 2578-2585
61. Shuster S., Frost G.I., Csoka A.B., Formby B., and Stern R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 102 (2002) 192-197
62. Standal T., Hjorth-Hansen H., Rasmussen T T., Dahl I.M., Lenhoff S., Brenne A.T., et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 89 (2004) 174-182
63. Carlinfante G., Vassiliou D., Svensson O., Wendel M., Heingard D., and Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin. Exp. Metastasis 20 (2003) 437-444
64. Fisher J.L., Field C.L., Zhou H., Harris T.L., Henderson M.A., and Choong P.F. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res. Treat. 61 (2000) 1-12
65. Adwan H., Bauerle T.J., and Berger M.R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 11 (2004) 109-120
66. Kim M., Park M., Moon E., Kim S., Lee C., Yoo H., Shin S., Song E., and Lee S. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer Res. 65 (2005) 686-691
67. Lin Y.H., and Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signalling pathway. J. Biol. Chem. 276 (2001) 46024-46030
68. Bates R.C., Edwards N.S., Burns G.F., and Fisher D.E. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 61 (2001) 5275-5283
69. Sohara Y., Ishiguro N., Machida K., Kurata H., Thant A.A., Senga T., et al. Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumour specific manner. Mol. Biol. Cell 12 (2001) 1859-1868
70. Fujita Y., Kitagawa M., Nakamura S., Azuma K., Ishii G., Higashi M., et al. CD44 signalling through focal adhesion kinase and its anti-apoptotic effect. Fed. Eur. Biochem. Soc. Lett. 528 (2002) 101-108